AR114236A1 - Inhibidores de la gcn2 y usos de los mismos - Google Patents
Inhibidores de la gcn2 y usos de los mismosInfo
- Publication number
- AR114236A1 AR114236A1 ARP190100196A ARP190100196A AR114236A1 AR 114236 A1 AR114236 A1 AR 114236A1 AR P190100196 A ARP190100196 A AR P190100196A AR P190100196 A ARP190100196 A AR P190100196A AR 114236 A1 AR114236 A1 AR 114236A1
- Authority
- AR
- Argentina
- Prior art keywords
- sulfur
- nitrogen
- oxygen
- independently selected
- membered
- Prior art date
Links
- 101000926525 Homo sapiens eIF-2-alpha kinase GCN2 Proteins 0.000 title 1
- 102100034175 eIF-2-alpha kinase GCN2 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 22
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 20
- 125000005842 heteroatom Chemical group 0.000 abstract 20
- 229910052757 nitrogen Inorganic materials 0.000 abstract 20
- 229910052717 sulfur Chemical group 0.000 abstract 20
- 239000011593 sulfur Chemical group 0.000 abstract 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 19
- 229910052760 oxygen Inorganic materials 0.000 abstract 19
- 239000001301 oxygen Chemical group 0.000 abstract 19
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 18
- 125000000623 heterocyclic group Chemical group 0.000 abstract 9
- 125000002950 monocyclic group Chemical group 0.000 abstract 7
- 229920006395 saturated elastomer Polymers 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000001931 aliphatic group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000002619 bicyclic group Chemical group 0.000 abstract 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 2
- 125000002837 carbocyclic group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862623312P | 2018-01-29 | 2018-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR114236A1 true AR114236A1 (es) | 2020-08-05 |
Family
ID=67392742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190100196A AR114236A1 (es) | 2018-01-29 | 2019-01-29 | Inhibidores de la gcn2 y usos de los mismos |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10793563B2 (https=) |
| EP (1) | EP3746071A4 (https=) |
| JP (2) | JP7377207B2 (https=) |
| KR (1) | KR20200115620A (https=) |
| CN (2) | CN117659010A (https=) |
| AR (1) | AR114236A1 (https=) |
| AU (2) | AU2019212969B2 (https=) |
| BR (1) | BR112020015396A2 (https=) |
| CA (1) | CA3089769A1 (https=) |
| IL (2) | IL276147B2 (https=) |
| MX (2) | MX2020007797A (https=) |
| SG (1) | SG11202006832YA (https=) |
| TW (1) | TW201940481A (https=) |
| WO (1) | WO2019148136A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX388576B (es) | 2016-06-07 | 2025-03-20 | Jacobio Pharmaceuticals Co Ltd | Derivados heterociclicos novedosos utiles como inhibidores de shp2. |
| EA202190196A1 (ru) | 2017-03-23 | 2021-08-31 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| JP7229257B2 (ja) | 2018-01-29 | 2023-02-28 | メルク パテント ゲーエムベーハー | Ｇｃｎ２阻害剤およびその使用 |
| BR112020015396A2 (pt) | 2018-01-29 | 2020-12-08 | Merck Patent Gmbh | Inididores de gcn2 e usos dos mesmos |
| WO2020010451A1 (en) * | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| US20210393623A1 (en) | 2018-09-26 | 2021-12-23 | Jacobio Pharmaceuticals Co., Ltd. | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
| GB202008749D0 (en) | 2020-06-09 | 2020-07-22 | Ip2Ipo Innovations Ltd | Novel compounds |
| CN116546984A (zh) * | 2020-09-28 | 2023-08-04 | 耶鲁大学 | 5-ht2a受体的选择性激动剂及其使用方法 |
| GB202104635D0 (en) | 2021-03-31 | 2021-05-12 | Imperial College Innovations Ltd | Methods and compositions for identifying and treating GCN2-dependent cancers |
| US20250000859A1 (en) | 2021-08-25 | 2025-01-02 | Alesta Therapeutics BV | Use of gcn2 inhibitors in treating cancer |
| CA3225500A1 (en) | 2021-10-04 | 2023-04-13 | Ulrich Luecking | Parg inhibitory compounds |
| GB202118096D0 (en) | 2021-12-14 | 2022-01-26 | Ip2Ipo Innovations Ltd | Novel compounds |
| AU2023269328A1 (en) | 2022-05-11 | 2024-12-12 | Ip2Ipo Innovations Limited | Gcn2 inhibitorr |
| CA3258667A1 (en) * | 2022-06-10 | 2023-12-14 | Interline Therapeutics Inc. | IMIDAZO(1,2-A)PYRIDINE DERIVATIVES USED AS RIPK2 INHIBITORS |
| TWI878939B (zh) * | 2022-06-29 | 2025-04-01 | 大陸商杭州聖域生物醫藥科技有限公司 | 五元並六元含氮化物、其中間體、製備方法和應用 |
| US12240836B2 (en) * | 2022-07-05 | 2025-03-04 | Dong-A St Co., Ltd. | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof |
| KR20250073643A (ko) | 2022-10-03 | 2025-05-27 | 포알엑스 테라퓨틱스 아게 | Parg 억제 화합물 |
| EP4688159A1 (en) | 2023-04-05 | 2026-02-11 | FoRx Therapeutics AG | Parg inhibitory compounds |
| WO2024259945A1 (zh) * | 2023-06-19 | 2024-12-26 | 杭州圣域生物医药科技有限公司 | 五元并六元含氮化合物、其制备方法和应用 |
| CN121889393A (zh) | 2023-10-03 | 2026-04-17 | 福克斯治疗股份公司 | Parg抑制化合物 |
| JP2025068526A (ja) | 2023-10-16 | 2025-04-28 | 株式会社豊田中央研究所 | 精製システム |
| KR20250122240A (ko) | 2024-02-06 | 2025-08-13 | 한미약품 주식회사 | 신규한 함질소 헤테로고리 유도체 및 이의 용도 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
| US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
| US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| DE60037345T2 (de) | 1999-12-10 | 2008-11-13 | Pfizer Products Inc., Groton | Pyrrolo(2,3-d)pyrimidin-Verbindungen |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US7074801B1 (en) * | 2001-04-26 | 2006-07-11 | Eisai Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| DE60217322T2 (de) | 2001-04-27 | 2007-10-04 | Zenyaku Kogyo K.K. | Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält |
| WO2003000682A1 (en) * | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0212049D0 (en) * | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
| PT1536827E (pt) | 2002-08-14 | 2009-03-20 | Silence Therapeutics Ag | Utilização de proteína cinase n beta |
| UA80296C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| AU2004228668B2 (en) | 2003-04-03 | 2011-10-27 | Park Funding, Llc | PI-3 kinase inhibitor prodrugs |
| CA2526285A1 (en) | 2003-05-15 | 2004-12-23 | Arqule, Inc. | Inhibitors of p38 and methods of using the same |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| EP1692153A4 (en) | 2003-07-03 | 2007-03-21 | Univ Pennsylvania | INHIBITION OF EXPRESSION OF SYK-KINASE |
| UA83509C2 (en) | 2003-10-15 | 2008-07-25 | Оси Фармасьютикалз, Инк. | Imidazopyrazines as tyrosine kinase inhibitors |
| WO2005060571A2 (en) * | 2003-12-10 | 2005-07-07 | Merck & Co., Inc. | Antiprotozoal imidazopyridine compounds |
| AR049769A1 (es) | 2004-01-22 | 2006-09-06 | Novartis Ag | Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina |
| US8097020B2 (en) | 2004-02-27 | 2012-01-17 | Custom Spine, Inc. | Pedicle dynamic facet arthroplasty system and method |
| WO2005113556A1 (en) | 2004-05-13 | 2005-12-01 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| PT1812440E (pt) | 2004-11-04 | 2011-01-25 | Vertex Pharma | Pirazolo[1,5-a]pirimidinas úteis enquanto inibidores de proteínas cinases |
| AU2006206458B2 (en) | 2005-01-19 | 2012-10-25 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PL1888550T3 (pl) | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| US7989622B2 (en) | 2005-10-07 | 2011-08-02 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
| JP5191391B2 (ja) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| WO2007129161A2 (en) | 2006-04-26 | 2007-11-15 | F. Hoffmann-La Roche Ag | Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| CA2664375A1 (en) | 2006-09-28 | 2008-04-03 | Novartis Ag | Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use |
| JP2010508315A (ja) | 2006-10-30 | 2010-03-18 | ノバルティス アーゲー | 抗炎症剤としてのヘテロ環式化合物 |
| US8513276B2 (en) * | 2006-12-22 | 2013-08-20 | Astex Therapeutics Limited | Imidazo[1,2-a]pyridine compounds for use in treating cancer |
| GB0625826D0 (en) | 2006-12-22 | 2007-02-07 | Astex Therapeutics Ltd | New compounds |
| HRP20150642T1 (hr) * | 2006-12-22 | 2015-08-14 | Astex Therapeutics Limited | BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a |
| KR101566840B1 (ko) | 2007-03-12 | 2015-11-06 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| AR066477A1 (es) | 2007-05-09 | 2009-08-19 | Novartis Ag | Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| ATE522249T1 (de) | 2007-07-26 | 2011-09-15 | Novartis Ag | Organische verbindungen |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| AR068877A1 (es) | 2007-10-17 | 2009-12-09 | Novartis Ag | Derivados heterociclicos de imidazol |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| HUE029767T2 (en) | 2008-03-11 | 2017-04-28 | Incyte Holdings Corp | JAK inhibitor azetidine and cyclobutane derivatives |
| WO2009156652A1 (fr) | 2008-05-29 | 2009-12-30 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Structure en nid d'abeille a base de titanate d'aluminium |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| CN102123987A (zh) * | 2008-07-28 | 2011-07-13 | 吉里德科学公司 | 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| TWI491610B (zh) * | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP2012521354A (ja) * | 2009-03-20 | 2012-09-13 | アムジエン・インコーポレーテツド | Ｐｉ３キナーゼの阻害薬 |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| KR101774035B1 (ko) | 2009-10-30 | 2017-09-01 | 얀센 파마슈티카 엔.브이. | 이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도 |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US8673905B2 (en) | 2011-03-17 | 2014-03-18 | Hoffmann-La Roche Inc. | Imidazo pyrazines |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| CA2863717C (en) | 2012-02-21 | 2021-09-28 | Lars Burgdorf | Furopyridine derivatives |
| CN104114557B (zh) | 2012-02-21 | 2017-10-24 | 默克专利股份公司 | 作为syk酪氨酸激酶抑制剂和gcn2丝氨酸激酶抑制剂的8‑取代2‑氨基‑[1,2,4]三唑并[1,5‑a]吡嗪 |
| US20150051202A1 (en) * | 2012-03-07 | 2015-02-19 | Merck Patent Gmbh | Triazolopyrazine derivatives |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| EP2920177A1 (en) | 2012-11-19 | 2015-09-23 | Novartis AG | Compounds and compositions for the treatment of parasitic diseases |
| CA2890911A1 (en) * | 2013-01-10 | 2014-07-17 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| EP2964648B1 (en) | 2013-03-05 | 2016-11-16 | Merck Patent GmbH | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents |
| WO2015091531A1 (en) * | 2013-12-19 | 2015-06-25 | Almirall, S.A. | Imidazolopyrimidin-2-yl derivatives as jak inhibitors |
| WO2016071293A2 (en) | 2014-11-03 | 2016-05-12 | Iomet Pharma Ltd | Pharmaceutical compound |
| JP6853619B2 (ja) | 2015-01-16 | 2021-03-31 | 大塚製薬株式会社 | シアノトリアゾール化合物の医薬用途 |
| TWI788655B (zh) * | 2015-02-27 | 2023-01-01 | 美商林伯士拉克許米公司 | 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途 |
| USRE50776E1 (en) * | 2015-03-27 | 2026-02-03 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| CN108290860B (zh) | 2015-11-25 | 2021-08-10 | Ucb生物制药有限责任公司 | 作为plasmepsin v抑制剂的亚氨基四氢嘧啶酮衍生物 |
| US11427590B2 (en) | 2017-01-06 | 2022-08-30 | The Johns Hopkins University | Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases |
| US11111245B2 (en) * | 2017-02-01 | 2021-09-07 | Aucentra Therapeutics Pty Ltd | Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents |
| JP7229257B2 (ja) | 2018-01-29 | 2023-02-28 | メルク パテント ゲーエムベーハー | Ｇｃｎ２阻害剤およびその使用 |
| BR112020015396A2 (pt) | 2018-01-29 | 2020-12-08 | Merck Patent Gmbh | Inididores de gcn2 e usos dos mesmos |
-
2019
- 2019-01-28 BR BR112020015396-6A patent/BR112020015396A2/pt not_active IP Right Cessation
- 2019-01-28 CA CA3089769A patent/CA3089769A1/en active Pending
- 2019-01-28 AU AU2019212969A patent/AU2019212969B2/en active Active
- 2019-01-28 MX MX2020007797A patent/MX2020007797A/es unknown
- 2019-01-28 US US16/260,019 patent/US10793563B2/en active Active
- 2019-01-28 WO PCT/US2019/015473 patent/WO2019148136A1/en not_active Ceased
- 2019-01-28 CN CN202311661189.4A patent/CN117659010A/zh active Pending
- 2019-01-28 TW TW108103175A patent/TW201940481A/zh unknown
- 2019-01-28 SG SG11202006832YA patent/SG11202006832YA/en unknown
- 2019-01-28 CN CN201980019854.5A patent/CN111867581B/zh active Active
- 2019-01-28 EP EP19743802.1A patent/EP3746071A4/en active Pending
- 2019-01-28 IL IL276147A patent/IL276147B2/en unknown
- 2019-01-28 JP JP2020541375A patent/JP7377207B2/ja active Active
- 2019-01-28 KR KR1020207025021A patent/KR20200115620A/ko not_active Withdrawn
- 2019-01-29 AR ARP190100196A patent/AR114236A1/es not_active Application Discontinuation
-
2020
- 2020-06-22 US US16/907,622 patent/US12084438B2/en active Active
- 2020-07-23 MX MX2023008031A patent/MX2023008031A/es unknown
-
2023
- 2023-10-27 JP JP2023184637A patent/JP2023178494A/ja active Pending
-
2024
- 2024-05-07 IL IL312674A patent/IL312674B1/en unknown
- 2024-07-17 US US18/775,203 patent/US20250059190A1/en active Pending
-
2025
- 2025-02-03 AU AU2025200711A patent/AU2025200711A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023008031A (es) | 2023-07-14 |
| CN111867581B (zh) | 2023-12-26 |
| IL276147A (en) | 2020-09-30 |
| JP2023178494A (ja) | 2023-12-14 |
| BR112020015396A2 (pt) | 2020-12-08 |
| JP2021512078A (ja) | 2021-05-13 |
| KR20200115620A (ko) | 2020-10-07 |
| US10793563B2 (en) | 2020-10-06 |
| EP3746071A1 (en) | 2020-12-09 |
| SG11202006832YA (en) | 2020-08-28 |
| US20210040083A1 (en) | 2021-02-11 |
| CN117659010A (zh) | 2024-03-08 |
| WO2019148136A1 (en) | 2019-08-01 |
| IL276147B1 (en) | 2024-06-01 |
| AU2019212969B2 (en) | 2025-01-23 |
| RU2020128586A (ru) | 2022-03-03 |
| CA3089769A1 (en) | 2019-08-01 |
| JP7377207B2 (ja) | 2023-11-09 |
| US20250059190A1 (en) | 2025-02-20 |
| TW201940481A (zh) | 2019-10-16 |
| US12084438B2 (en) | 2024-09-10 |
| IL312674A (en) | 2024-07-01 |
| IL276147B2 (en) | 2024-10-01 |
| AU2019212969A1 (en) | 2020-08-13 |
| AU2025200711A1 (en) | 2025-02-20 |
| US20190233411A1 (en) | 2019-08-01 |
| CN111867581A (zh) | 2020-10-30 |
| MX2020007797A (es) | 2020-09-18 |
| IL312674B1 (en) | 2026-03-01 |
| EP3746071A4 (en) | 2021-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR114236A1 (es) | Inhibidores de la gcn2 y usos de los mismos | |
| AR114235A1 (es) | Inhibidores de gcn2 y usos de los mismos | |
| AR106798A1 (es) | Inhibidores pirazol de acc y usos de los mismos | |
| AR096243A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR096242A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR098136A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR106799A1 (es) | Inhibidores éster de acc y usos de los mismos | |
| AR103138A1 (es) | Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos | |
| AR106806A1 (es) | Inhibidores triazol de acc y usos de los mismos | |
| AR106472A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR096241A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR114828A1 (es) | Compuestos de pteridinona y sus usos | |
| AR109560A1 (es) | Compuestos moduladores de receptores tipo toll | |
| AR095192A1 (es) | Quinolina y quinazolinamidas como modulares de canales de sodio | |
| AR091273A1 (es) | Inhibidores de pirimidinil tirosina quinasa | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR091976A1 (es) | Inhibidores de proteasa ns3 de vhc | |
| AR104555A1 (es) | SULFONAS TRICÍCLICAS COMO MODULARES DE RORg | |
| AR112900A1 (es) | Compuesto derivado de pirazol y uso de este | |
| AR117472A1 (es) | Inhibidores de tienopiridina de ripk2 | |
| AR103414A1 (es) | Derivados de hidroxialquil-piperazina como moduladores del receptor cxcr3 | |
| AR106185A1 (es) | Compuestos macrocíclicos de sulfondiimina | |
| AR095202A1 (es) | Heterociclos como moduladores de la actividad quinasa | |
| AR100767A1 (es) | Agentes moduladores de la atx | |
| AR105460A1 (es) | Derivados sustituidos de 2-pirimidina furano / tienocicloalquilamino y su uso para el control del crecimiento de plantas no deseables |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |